Viewing Study NCT05291702


Ignite Creation Date: 2025-12-25 @ 3:39 AM
Ignite Modification Date: 2026-05-18 @ 1:54 PM
Study NCT ID: NCT05291702
Status: UNKNOWN
Last Update Posted: 2022-03-23
First Post: 2022-01-30
Is Gene Therapy: True
Has Adverse Events: False

Brief Title: Multitract Percutaneous Nephrolithotomy(PCNL) in Large Renal Stones.
Sponsor: Assiut University
Organization:

Study Overview

Official Title: Multitract PCNL as One Step for Management of Large Renal Stones
Status: UNKNOWN
Status Verified Date: 2022-03
Last Known Status: NOT_YET_RECRUITING
Delayed Posting: No
If Stopped, Why?: Not Stopped
Has Expanded Access: False
If Expanded Access, NCT#: N/A
Has Expanded Access, NCT# Status: N/A
Acronym: PCNL
Brief Summary: Investigator aimed to analyze the clinical efficacy and safety of multiple tracts PCNL as one step therapy to treat the staghorn stones or multiple calyceal calculi which are inaccessible by single tract
Detailed Description: Staghorn calculi are branched stones either partial or complete occupying the pelvis and one or more of the renal caliceal system that is detected by non contrast computrized tomography (NCCT) and plain on kidney, ureter, urinary bladder (KUB). An untreated staghorn calculus over time can damage the kidney and deteriorate its function and /or cause life threatening sepsis.

Total stone clearance is an important goal to eradicate any infective focus, relieve obstruction and preserve the kidney function.

Based on American Urological Association (AUA) guideline, PCNL is the most effective, safest and minimally invasive treatment option compared to open surgery

Study Oversight

Has Oversight DMC: None
Is a FDA Regulated Drug?: False
Is a FDA Regulated Device?: False
Is an Unapproved Device?: None
Is a PPSD?: None
Is a US Export?: None
Is an FDA AA801 Violation?: